SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
INTI

Inhibitor Therapeutics, Inc. (OTC:INTI)

US · Delayed Price · Currency is USD
Also listed: CBTEHealthcare · Biotechnology
$0.08+$0.00 (+0.00%)
 
Market cap
$13.9M
Insider Score
Health Score
Listed since
Sep 13, 2013
Market Cap$13.90M+60.0%
Revenue (ttm)$0
Net Income-$3.19M+7.0%
EPS-$0.02+7.5%
Shares Out173.79M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume80,000
Open$0.08
Previous Close$0.08
Day's Range$0.08 - $0.08
52-Week Range$0.04 - $0.12
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a
No price history available.

About INTI

Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.

Address
3014 West Palmira Avenue, Tampa, FL, 33629-7264, US
Market Cap
14 million
Employees
8
Industrial Classification
Biotechnology
Financial Health Score
Distressed
From INTI’s reported statements · Q3 2026 (trailing 12 months) · 3 of 5 pillars
1 Day
+0.00%
5 Days
+0.00%
1 Month
-10.11%
6 Months
+0.83%
1 Year
+60.00%

$INTI stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in INTI holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by INTI's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

INTI Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New INTI patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to INTI from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from INTI’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.